valsartan has been researched along with Glucose Metabolic Disorder in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Blaak, EE; Diamant, M; Goossens, GH; Moors, CC; van der Zijl, NJ | 1 |
Califf, RM; Giles, T; Haffner, SM; Hernandez, AF; Krum, H; Leiter, LA; Martinez, FA; Mazzone, T; McMurray, JJ; Rutten, GE; Standl, E; Sun, JL; Thomas, L; Tognoni, G; Wong, YW | 1 |
2 trial(s) available for valsartan and Glucose Metabolic Disorder
Article | Year |
---|---|
The effects of long-term valsartan treatment on skeletal muscle fatty acid handling in humans with impaired glucose metabolism.
Topics: Angiotensin II Type 1 Receptor Blockers; Biopsy; Carbon Radioisotopes; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Forearm; Gene Expression Regulation; Glucose Metabolism Disorders; Humans; Lipid Metabolism; Male; Muscle Proteins; Muscle, Skeletal; Oxidation-Reduction; Postprandial Period; RNA, Messenger; Tetrazoles; Tritium; Valine; Valsartan | 2013 |
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Topics: Adiposity; Aged; Albuminuria; Biomarkers; Blood Glucose; Creatinine; Cyclohexanes; Double-Blind Method; Female; Glucose Metabolism Disorders; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Linear Models; Male; Middle Aged; Multivariate Analysis; Nateglinide; Nonlinear Dynamics; Obesity, Abdominal; Phenylalanine; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Waist Circumference | 2013 |